抗HERV-K102-SU鼠源抗体及其用途
By developing a murine monoclonal antibody that specifically binds to HERV-K102-Env-SU, the problem of decreased binding activity of antibodies during glycosylation or conformational changes in existing technologies has been solved, achieving efficient recognition of HERV-K102-Env-SU and therapeutic effects on related diseases.
CN119751661BActive Publication Date: 2026-07-17ZHEJIANG UNIV
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- ZHEJIANG UNIV
- Filing Date
- 2024-12-16
- Publication Date
- 2026-07-17
AI Technical Summary
Technical Problem
Current technologies lack effective treatments for tumors, neurodegenerative diseases, and autoimmune diseases caused by abnormal expression of the HERV-K102 subtype envelope protein SU, and existing antibody drugs exhibit decreased binding activity upon glycosylation or conformational changes.
Method used
A murine monoclonal antibody was developed that specifically binds to the conserved region of HERV-K102-Env-SU, can recognize both natural and denatured forms of the antigen protein, and has high antigen-binding activity.
Benefits of technology
It achieves efficient recognition and binding of HERV-K102-Env-SU, suitable for the diagnosis and treatment of related diseases, and has higher antigen binding activity and stability.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN119751661B_ABST
Abstract
本发明属于生物技术领域，具体涉及抗HERV‑K102‑SU鼠源抗体及其用途。本发明涉及针对人内源性逆转录病毒HERV‑K102亚型包膜蛋白SU的新型抗体及其在诊断和 / 或治疗中的用途，所述抗体靶向不受糖基化或天然构象影响的保守区。这些抗体已经在ELISA，FCM(流式细胞术)和蛋白质印迹免疫测定中证实了其生物活性。这些抗体不仅识别天然和变性的HERV‑K102‑Env‑SU抗原蛋白，而且也识别非糖基化和糖基化形式。
Need to check novelty before this filing date? Find Prior Art